Scientific References

Check out the scientific literature that supports our molecular targets and our synthetic lethal approach.

June 2023

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

September 2022

Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ

July 2022

Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306

July 2022

Guiding ATR and PARP inhibitor combinationswith chemogenomic screens

April 2022

CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition

We have a number of synthetic lethal therapies in development.